Does UPADACITINIB Cause Malignant neoplasm progression? 15 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 15 reports of Malignant neoplasm progression have been filed in association with UPADACITINIB (Rinvoq). This represents 0.0% of all adverse event reports for UPADACITINIB.
15
Reports of Malignant neoplasm progression with UPADACITINIB
0.0%
of all UPADACITINIB reports
3
Deaths
4
Hospitalizations
How Dangerous Is Malignant neoplasm progression From UPADACITINIB?
Of the 15 reports, 3 (20.0%) resulted in death, 4 (26.7%) required hospitalization, and 3 (20.0%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for UPADACITINIB. However, 15 reports have been filed with the FAERS database.
What Other Side Effects Does UPADACITINIB Cause?
Pain (4,444)
Arthralgia (3,815)
Drug ineffective (3,384)
Covid-19 (2,978)
Rheumatoid arthritis (2,730)
Pain in extremity (2,353)
Fatigue (2,153)
Fall (2,081)
Surgery (2,037)
Therapy interrupted (1,741)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which UPADACITINIB Alternatives Have Lower Malignant neoplasm progression Risk?
UPADACITINIB vs URAPIDIL
UPADACITINIB vs UREA
UPADACITINIB vs URIDINE TRIACETATE
UPADACITINIB vs UROFOLLITROPIN
UPADACITINIB vs URSODIOL